Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib Combined With Rituximab and Lenalidomide (ZR2) Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma: A Randomized, Multicenter, Open-Label Phase II Clinical Study

NCT07505849 is registered in ClinicalTrials.gov with KeshuZhou as lead sponsor.

NCT NCT07505849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07505849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib Combined With Rituximab and Lenalidomide (ZR2) Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma: A Randomized, Multicenter, Open-Label Phase II Clinical Study
Lead sponsor
KeshuZhou
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 23, 2026
Completion date
March 23, 2030
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphomas